Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Teduglutide reduces need for parenteral support in short bowel syndrome

Teduglutide reduces the need for parenteral fluids among patients with short bowel syndrome with intestinal failure, reports December's issue of Gastroenterology.

News image

Teduglutide, a glucagon-like peptide 2 analogue, might restore intestinal structural and functional integrity by promoting growth of the mucosa and reducing gastric emptying and secretion.

These factors could increase fluid and nutrient absorption in patients with short bowel syndrome with intestinal failure.

Dr Palle Jeppesen and colleagues performed a prospective study to determine whether teduglutide reduces parenteral support in patients with short bowel syndrome with intestinal failure.

The researchers performed a 24-week study of patients with short bowel syndrome with intestinal failure who were given subcutaneous teduglutide or placebo once daily.

Parenteral support was reduced if 48-hour urine volumes exceeded baseline values by 10% or more.

The mean reduction in parenteral support volume in the teduglutide group was 4 L per week 
Gastroenterology

The primary efficacy end point was number of responders.

The team found significantly more responders in the teduglutide group than the placebo group.

At week 24, the mean reduction in parenteral support volume in the teduglutide group was 4 L per week compared with 2 L per week in the placebo group.

The percentage of patients with a 1-day or more reduction in the weekly need for parenteral support was greater in the teduglutide group than in the placebo group.

The research team observed that teduglutide increased plasma concentrations of citrulline, a biomarker of mucosal mass.

The team noted that the distribution of treatment-emergent adverse events that led to study discontinuation was similar between patients given teduglutide, and placebo.

Dr Jeppesen's team commented, "The 24-weeks of teduglutide treatment was generally well tolerated in patients with short bowel syndrome with intestinal failure."

"Treatment with teduglutide reduced volumes and numbers of days of parenteral support for patients with short bowel syndrome with intestinal failure."

Gastroenterology 2012: 143(6): 1473-1481.e3
28 November 2012

Go to top of page Email this page Email this page to a colleague

 30 January 2015

Advanced search
 30 January 2015 
HIV-associated NAFLD and primary NAFLD
 30 January 2015 
Narcotic use in children with IBD
 30 January 2015 
Removal of rectal neoplasms
 29 January 2015 
Pyloric compliance in gastroparesis
 29 January 2015 
Gastric cancer in peptic ulcer disease
 29 January 2015 
Genetics and risk of Barrett's
 28 January 2015 
Metabolic syndrome in celiac disease
 28 January 2015 
Remission in Crohn's disease
 28 January 2015 
Surgery and quality of life in rectal cancer
 27 January 2015 
Outcomes for liver transplantation
 27 January 2015 
Psychological distress and fecal composition in IBS
 27 January 2015 
Risk of upper GI cancers in GERD
 26 January 2015 
Breath analysis for IBD
 26 January 2015 
Fecal microbiota transplantation
 26 January 2015 
Antidepressants and GERD
 23 January 2015 
Liver transplant outcomes
 23 January 2015 
Breath analysis in IBD
 23 January 2015 
Fecal microbiota transplantation
 22 January 2015 
NASH and lipid improvements
 22 January 2015 
NAFLD and NASH with psoriasis
 22 January 2015 
Predicting outcomes in HCV-related advanced liver disease
 21 January 2015 
Colon capsule versus CT colonography
 21 January 2015 
Barrett's esophagus screening in the community
 21 January 2015 
Portal vein obstruction
 20 January 2015 
Modulating mucosal damage in Crohn's
 20 January 2015 
Novel techniques for Barrett's screening
 20 January 2015 
Food intolerance
 19 January 2015 
Treatment of fecal incontinence
 19 January 2015 
Hepatic cyst infection
 19 January 2015 
Risk of IBS among relatives
 16 January 2015 
Colorectal cancer screening uptake
 16 January 2015 
NAFLD and NASH in patients with psoriasis
 16 January 2015 
Fecal incontinence
 15 January 2015 
Coffee intake and liver disease
 15 January 2015 
NAFLD in primary care practice
 15 January 2015 
Management of univestigated dyspepsia
 14 January 2015 
Missed colorectal cancers after colonoscopy with polypectomy
 14 January 2015 
Inflixmab response in Crohn's
 14 January 2015 
Statins and liver injury in chronic liver disease
 13 January 2015 
Cytomegalovirus in IBD
 13 January 2015 
Helicobacter-negative gastritis
 13 January 2015 
Hep B vaccine in IBD
 12 January 2015 
Survival in Hep B virus-related hepatocellular carcinoma
 12 January 2015 
Relapse of Crohn's disease after surgery
 12 January 2015 
Late liver metastases of colorectal cancer
 09 January 2015 
Fecal microbiota transplantation for refractory Crohn's
 09 January 2015 
Hypercoagulability after liver resection
 09 January 2015 
Naps and gastroesophageal reflux vs nocturnal sleep
 08 January 2015 
Post-infectious functional dyspepsia
 08 January 2015 
Diagnosis of liver iron overload
 08 January 2015 
Digestive tract damage in Crohn's disease
 07 January 2015 
Early-onset colorectal cancer
 07 January 2015 
SSRIs for noncardiac chest pain
 07 January 2015 
SSRIs and upper GI bleeds
 06 January 2015 
Detection of inflammation in Crohn's
 06 January 2015 
Leptin and early-onset extreme obesity
 06 January 2015 
Goals of IBD treatment
 19 December 2014 
Thiopurine treatment and colectomy in ulcerative colitis
 19 December 2014 
Idiopathic inflammatory demyelinating disease in IBD
 19 December 2014 
Colorectal cancer risk for first-degree relatives

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us